Kevin Ganong, MD
Endocrinology, Diabetes & Metabolism · Jonesboro, ARNPI 1699730762
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $122,025 of the $131,358 with a category attached, or 92.9%. AstraZeneca accounts for 96.8% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2021 at $45,721 and has fallen 99.0% since, to $444 in 2025. Among endocrinology, diabetes & metabolism clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 298 payments — averaging $440.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$127K
- Medtronic$1K
- Sanofi-aventis U.S. LLC$520
- Bayer$488
- Novo Nordisk$427
- Lilly USA, LLC$411
- plus $1K from 15 others
What the payments were for
- Speaking & faculty fees$122,02593%
- Travel & lodging$2,8782%
- Food & beverage$6,4435%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 181 | $127,205 |
| Medtronic(2 entities) | 20 | $1,112 |
| Sanofi-aventis U.S. LLC | 20 | $520 |
| Bayer | 15 | $488 |
| Novo Nordisk | 5 | $427 |
| Lilly USA, LLC | 20 | $411 |
| Amgen(2 entities) | 5 | $335 |
| Corcept Therapeutics | 3 | $146 |
| Novartis | 3 | $125 |
| Abbott | 1 | $94 |
| Radius Health, Inc. | 1 | $86 |
| Boehringer Ingelheim | 5 | $70 |
| Sequel Med Tech, LLC | 3 | $62 |
| BETA Bionics, Inc. | 1 | $57 |
| Nevro Corp. | 3 | $51 |
| Antares Pharma, Inc. | 3 | $44 |
| Dexcom, Inc. | 3 | $39 |
| Merck | 2 | $29 |
| Astellas Pharma US Inc | 2 | $29 |
| Tandem Diabetes Care, Inc. | 1 | $18 |
| Insulet Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$131,358 in reported general payments places this provider in the 90th percentile of 43 endocrinology, diabetes & metabolism providers in Arkansas.
See all endocrinology, diabetes & metabolism providers in Arkansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 284 | $327,240 |
| MycapssaOctreotide Acetate | 14 | $181,234 |
| MounjaroTirzepatide | 151 | $178,948 |
| FarxigaDapagliflozin Propanediol | 167 | $139,770 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 128 | $124,313 |
| TrulicityDulaglutide | 95 | $109,481 |
| JardianceEmpagliflozin | 102 | $86,121 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 41 | $78,977 |
| Tresiba Flextouch U-200Insulin Degludec | 58 | $73,514 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 118 | $58,435 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 64 | $53,305 |
| GlyxambiEmpagliflozin/Linagliptin | 73 | $53,246 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 74 | $50,470 |
| FiaspInsulin Aspart (Niacinamide) | 42 | $43,460 |
| JanuviaSitagliptin Phosphate | 67 | $40,891 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Rybelsus, Novolog | $427 | $404,874372 claims |
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog, Insulin Lispro | $411 | $328,077373 claims |
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta | $70 | $147,657191 claims |
| AstraZenecaFarxiga | $127,205 | $139,770167 claims |
| MerckJanuvia, Janumet Xr, Janumet | $29 | $66,937104 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $520 | $26,44832 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 43 endocrinology, diabetes & metabolism providers in Arkansas.
Other endocrinology, diabetes & metabolism in Jonesboro
- Chitharanjan DuvoorJonesboro$76K
- Richard GriffithsLittle Rock$925K
- Catherine KilpatrickFayetteville$690K
- Adam MaassSpringdale$502K
- James ThrasherLittle Rock$349K
- Cory GambleFort Smith$112K
- Richard RappLittle Rock$47K
- Shunzhong BaoLittle Rock$40K
- Jason DailyFayetteville$35K
- Daryl BurrowsHot Springs$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.